Recon: J&J’s lung cancer combo bests AstraZeneca’s Tagrisso in study; Galen robot gains clearance for ENT surgeries

• FDA advisers vote overwhelmingly against ALS treatment from BrainStorm (STAT)
• Wegovy, other weight-loss drugs scrutinized over reports of suicidal thoughts (Reuters)
• Ozempic label now notes potential side effect of intestinal blockage (Reuters)
• Did the government get a bad deal on the Covid-19 boosters? (STAT)
• US channels $104m into antimicrobial resistance project (Pharmaphorum)
• Flu, Covid vaccination rates decline, as U.S. health officials make new push for inoculations (STAT)
• As government shutdown looms, medical device reviews expected to continue (MedTech Dive)
• 'We can't forget about this': As chemotherapy shortage ebbs and flows, attention shifts to long-term solutions (Fierce Pharma)
• UPDATED: Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will (Fierce Pharma)

• Pharma lobby says EU ban on 'forever chemicals' would halt drug production (Reuters)
• Schott Pharma shares jump 11% on Frankfurt trading debut (Reuters)
• Commission Text Clarifying Timelines For Annex XVI Devices May Leave Companies Dazed (MedTech Insight)
• Hermes Pharma earmarks €25M to expand oral drug production capacity (Fierce Pharma)

• A STAT analysis shows how top drug companies are starting to take action on climate (STAT)
• Biogen shutters digital health group, nixes Apple study, as part of cost cuts (STAT)
• Gene therapy death was caused by an unknown risk of the virus used, study suggests (STAT)
• Newer antibiotic effective against deadly staph infection in trial (Reuters)
• GSK lifts growth target for HIV business on demand for long-acting drug (Reuters)
• J&J's lung cancer therapy succeeds in head-to-head study with AstraZeneca's drug (Reuters)
• Bluebird taps Lonza to boost manufacturing capacity for its gene therapies Zynteglo, Skysona (Fierce Pharma)
• Regulatory tracker: Akebia refiles oral anemia drug with FDA (Fierce Pharma)

• Machine learning could help predict risk of preterm birth using wearables data (STAT)
• Harbinger Health raises $140M to study blood-based cancer screening test (MedTech Dive)
• Artificial heart maker’s cash runway shrinks to 1 month after supply woes hurt sales (MedTech Dive)
• Galen robot gets FDA de novo clearance for ENT surgeries (MedTech Dive)
• Minute Insight: Vicarious’ Future Gets Precarious (MedTech Insight)
• Oxford Biodynamics Releases EpiSwitch Prostate Cancer Test Early (MedTech Insight)

• CVS Faces Suit from Local Pharmacy Over ‘One-Sided’ Contracts (Bloomberg Law)
• CureVac claims advantage in BioNTech patent dispute (Pharmaphorum)
• Drug industry payments to eye docs boosted Medicare spending on pricier treatments (STAT)
• Congress could stop free public access to government-funded research (STAT)
• FDA’s International Harmonization Plan Points To Ongoing Priorities (MedTech Insight)